RxSight $115 million follow-on offering
The stock is listed on the Nasdaq Global Market
Davis Polk advised the sole representative of the several underwriters in connection with a public offering by RxSight, Inc. of 2,053,571 shares of common stock, which included 267,857 shares of common stock from the full exercise of the underwriters’ option to purchase additional shares, for total gross proceeds of approximately $115 million. The common stock is listed on the Nasdaq Global Market under the symbol “RXST.”
Based in Aliso Viejo, California, RxSight is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye and Rebecca Lei. Partner Frank J. Azzopardi and associates Adrian Rabin and Jay Krishnan provided intellectual property advice. Counsel Liang Zhang and associate Ted Lee provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York.